The effect of highly purified inhibitor of the first component of complement (CāINH), α2 macroglobulin (α2M), and α1 antitrypsin on the components of the fibrinolytic pathway in human plasma has been examined. CāINH was the only factor active upon the Hageman factor fragments functioning at the initial step of the fibrinolytic pathway, α2M was the only factor active against the plasminogen activator and the most active inhibitor of plasmin. The inhibition of plasmin by α2M appeared stoichiometric with one molecule of α2M inhibiting two molecules of plasmin. All three plasma inhibitors were active against plasmin.
Alan D. Schreiber, Allen P. Kaplan, K. Frank Austen
Usage data is cumulative from November 2023 through November 2024.
Usage | JCI | PMC |
---|---|---|
Text version | 119 | 0 |
70 | 25 | |
Figure | 0 | 2 |
Scanned page | 265 | 5 |
Citation downloads | 39 | 0 |
Totals | 493 | 32 |
Total Views | 525 |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.